Epithelial plasma membrane transporters as drug targets
Physiological Reviews · 01.07.2026 · 106 (3) · 1161-1194
DOI: 10.1152/physrev.00045.2025 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Physiological Reviews, erschienen am 01.07.2026. Verfasst von Alan S Verkman. Beteiligte Einrichtung: Departments of Medicine and Physiology, University of California, San Francisco, California, United States. Hauptthemen laut MEDLINE: Membrane Transport Proteins, Epithelial Cells, Drug Discovery, Cell Membrane. Die Arbeit nennt 191 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: HHS | National Institutes of Health (NIH), NIDDK NIH HHS, Guthy-Jackson Charitable Foundation.
Abstract (Originalsprache)
Small-molecule discovery and drug development are increasingly being pursued in academic settings, expanding beyond their traditional confinement to the pharmaceutical industry. The initial steps in drug discovery typically include identification and validation of a target, screening of chemical libraries to identify modulators of target activity, and subsequent prioritization and optimization of lead compounds using in vitro systems and animal models, with emphasis on compound potency, selectivity, and pharmacological properties. This review focuses on early-stage discovery of small molecules that target plasma membrane transporters on epithelial cells, including absorptive and secretory epithelia in kidney, gastrointestinal tract, lung, and eye. Of the estimated 500 distinct epithelial plasma membrane transporters, fewer than a dozen are the targets of approved drugs, most of which have been in clinical use for decades. We discuss the logistics and challenges associated with small-molecule discovery in an academic setting. Specific epithelial cell targets are considered, including chloride channels, solute-coupled transporters, urea transporters, and aquaporins, with therapeutic implications spanning constipation and secretory diarrheas, cystic fibrosis, dry eye disease, edema, hypertension, and kidney stones. We conclude by identifying unmet needs and outlining opportunities to enable next-generation pharmacological modulation of epithelial transport processes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Medicine and Physiology, University of California, San Francisco, California, United States.
ORCID-Profile: Alan S Verkman
Förderung
- HHS | National Institutes of Health (NIH)
- NIDDK NIH HHS
- Guthy-Jackson Charitable Foundation
- UCSF Invent Fund
- UCSF Catalyst Fund
- NEI NIH HHS
- NIBIB NIH HHS
- American Heart Association (AHA)
Zitieren
APA
Verkman, A. S. (2026). Epithelial plasma membrane transporters as drug targets. Physiological Reviews, 106(3), 1161-1194. https://doi.org/10.1152/physrev.00045.2025
Vancouver
Verkman AS. Epithelial plasma membrane transporters as drug targets. Physiological Reviews. 2026;106(3):1161-1194. doi:10.1152/physrev.00045.2025
BibTeX
@article{Verkman2026,
author = {Verkman, Alan S},
title = {Epithelial plasma membrane transporters as drug targets},
journal = {Physiological Reviews},
year = {2026},
volume = {106},
number = {3},
pages = {1161--1194},
doi = {10.1152/physrev.00045.2025}
}
EUVIMED